SC
VRTX icon

Scholtz & Company’s Vertex Pharmaceuticals VRTX Stock Holding History

Scholtz & Company’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-1,600
Closed -$651K – 67
2023
Q4 		$651K Buy
+1,600
New +$591K 0.32% 44

Other funds holding VRTX

Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

Scholtz & Company's VRTX Position: Q1 2024 in Review

Scholtz & Company sold out of Vertex Pharmaceuticals (VRTX) in Q1 2024, closing a stake of 1,600 shares — an estimated $651K sold.

Scholtz & Company first reported a position in VRTX in Q4 2023 and held it in 1 quarter. The position peaked at $651K in Q4 2023. 1,493 funds tracked by Wall St. Rank hold VRTX as of Q1 2024.

  • Scholtz & Company reported no remaining Vertex Pharmaceuticals position as of Q1 2024 after selling out during the quarter.
  • Scholtz & Company sold 1,600 Vertex Pharmaceuticals shares in Q1 2024, an estimated $651K.
  • Scholtz & Company first reported a position in Vertex Pharmaceuticals in Q4 2023 and held it in 1 quarter.
  • Scholtz & Company's Vertex Pharmaceuticals position peaked at $651K in Q4 2023.
  • 1,493 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q1 2024.

Based on Scholtz & Company's 13F filing for Q1 2024, filed 14 May 2024.